Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Hansoh Pharmaceutical Group Co Ltd
3692Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. Address: 287 Xiangke Road, Shanghai, China, 201210
Analytics
Zielpreis von Wall Street
149.11 HKDKGV
21.5181Dividendenrendite
1.97 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen 3692
Dividenden-Analyse 3692
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
2 JahreAusschüttungsquote 5-Jahres-Durchschnitt
27 %Verlauf der Dividende 3692
Bewertung der Aktie 3692
Finanzen 3692
Ergebnisse | 2019 | Dynamik |